PATENT CLAIM ANALYSIS

Application Number: 15887456
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-06
Patent Classification: ["424", "277100"]

Abstract:
A lymphoma cell line was engineered to express surface IgG1 Fc. These tumor cells were taken up rapidly by DCs, leading to enhanced cross-presentation of tumor-derived antigen to CD8 T cells. IgG1-Fc tumors failed to grow in vivo and prophylactic vaccination in an animal model resulted in rejection of unmanipulated tumor cells. Furthermore, IgG1-Fc tumor cells were able to slow the growth of an unmanipulated primary tumor when used as a therapeutic tumor vaccine. This demonstrates that engagement of Fc receptors by tumors expressing the Fc region of IgG1 can induce efficient and protective anti-tumor CD8+ T cell responses without prior knowledge of tumor-specific antigen.

Claim (Index 1):
A method of treating cancer in a subject comprising:\n (a) providing a recombinant cancer cell that expresses Ig Fc on its surface; and (b) administering said recombinant cancer cell to said subject.

Metadata:
- Claim Count in Document: 42.0
- Percentile: 88.0
- Lexical Diversity: 1.49333
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14021353', '15016375', '12933567', '11773162', '14158531']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7028472148421067
- 35 USC 102 Novelty (BERT): 0.5236892917436652
- Combined Prediction Score: 0.6849314225322626
- Mean Citation Score: 320.313956
- Max Citation Score: 332.7924
- Similarity Product: 228.2762229994297

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test